Santhera repositions omigapil and initiates clinical development program
Santhera Pharmaceuticals announced the initiation of a clinical program with omigapil. The drug candidate in-licensed from Novartis is repositioned for therapeutic use in Congenital Muscular Dystrophy (CMD). The clinical development program will be initiated with a Phase I study in pediatric CMD patients, according to the press release of Santhera. EndoStem, an EU 7th Framework Programme, and two patient organizations support the program with CHF 1.3 million. Patient enrolment is expected to start in late 2014. CMDs refer to a wide variety of inherited neuromuscular conditions characterized by different forms of progressive loss of muscle tissue. Currently, no pharmacological therapy is available or in advanced clinical development.
